Global Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2034
Global Urological Cancer Therapeutics Drugs Market is estimated to reach $48.6 billion by 2025 Says, .Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs.
Market Analysis and InsightsGlobal Urological Cancer Therapeutics Drugs Market
Global Urological Cancer Therapeutics Drugs market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Urological Cancer Therapeutics Drugs industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
Globally, Urological Cancer Therapeutics Drugs key companies include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. Novartis, Pfizer, Johnson & Johnson are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Urological Cancer Therapeutics Drugs were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Urological Cancer Therapeutics Drugs market and estimated to attract more attentions from industry insiders and investors.
Urological Cancer Therapeutics Drugs can be divided into Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib) and Votrient (pazopanib hydrochloride), etc. Xofigo (radium Ra 223 dichloride) is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Urological Cancer Therapeutics Drugs is widely used in various fields, such as Hospital, Medical Research Laboratory and Others,, etc. Hospital provides greatest supports to the Urological Cancer Therapeutics Drugs industry development. In 2022, global % revenue of Urological Cancer Therapeutics Drugs went into Hospital filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Urological Cancer Therapeutics Drugs market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Urological Cancer Therapeutics Drugs market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Segment by Type
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Hospital
Medical Research Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Urological Cancer Therapeutics Drugs introduction, etc. Urological Cancer Therapeutics Drugs Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Urological Cancer Therapeutics Drugs
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Urological Cancer Therapeutics Drugs Market
Global Urological Cancer Therapeutics Drugs market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Urological Cancer Therapeutics Drugs industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
Globally, Urological Cancer Therapeutics Drugs key companies include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. Novartis, Pfizer, Johnson & Johnson are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Urological Cancer Therapeutics Drugs were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Urological Cancer Therapeutics Drugs market and estimated to attract more attentions from industry insiders and investors.
Urological Cancer Therapeutics Drugs can be divided into Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib) and Votrient (pazopanib hydrochloride), etc. Xofigo (radium Ra 223 dichloride) is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Urological Cancer Therapeutics Drugs is widely used in various fields, such as Hospital, Medical Research Laboratory and Others,, etc. Hospital provides greatest supports to the Urological Cancer Therapeutics Drugs industry development. In 2022, global % revenue of Urological Cancer Therapeutics Drugs went into Hospital filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Urological Cancer Therapeutics Drugs market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Urological Cancer Therapeutics Drugs market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Segment by Type
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Segment by Application
Hospital
Medical Research Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Urological Cancer Therapeutics Drugs introduction, etc. Urological Cancer Therapeutics Drugs Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Urological Cancer Therapeutics Drugs
Chapter 13Methodology and Data Sources adopted by MRAResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices